PureTech, Boehringer partner to develop lymph node-targeting cancer immunotherapies

As part of its shift to focus on an internal pipeline in lieu of its previous affiliate model, PureTech partnered its lymphatic targeting platform with Boehringer Ingelheim Wednesday. The

Read the full 299 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE